最新ニュース Ayr Wellness (OTC:AYRWF) 株価情報

Ayr Wellness Inc is a vertically integrated, U.S. multi-state cannabis operator. IT engaged in the cultivation, manufacturer, and retailer of cannabis products and branded cannabis packaged goods. It operates in one operating segment, cannabis sales.

Ordinary Shares (Sub, Restricted, Ltd Voting)

Cannabis

Earnings

News

Retail Sales

Markets

AAWH

AYRWF

CRLBF

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

TRUL

VRNOF

2024年第2四半期の大部分の大麻企業の財務業績が出揃い、その結果から興味深いトレンドが浮かび上がってきた。その1つが、米国のマルチステート・オペレーター（MSO）が供給チェーンにおけるコストと効率を改善しているという点だ。

大麻関連企業の業績　供給チェーンにおけるコストと効率が改善

Government

Penny Stocks

Regulations

Emerging Markets

Politics

Small Cap

General

CCHWF

CNBS

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

TILT

ペンシルベニア州が最近承認した予算には、大麻企業であるJushi Holdings（OTC：JUSHF）およびTILT Holdings（OTC：TILT）のような企業にとって大きな打撃を与える、大麻の娯楽利用の合法化が除外されています。

ペンシルベニア州　大麻の娯楽利用合法化に制限掲示へ

Events

ロン・デサンティス氏は、11月に大麻合法化が認められると学校付近で大麻が流行る可能性があると警告

Ayr Wellness Inc

FORTY

Formula Sys (1985) Q3 EPS $1.51 Up From $1.00 YoY, Sales $699.9M Up From $654.8M YoY

Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) reported quarterly earnings of $0.57 per share. This is a 32.51 percent decrease over earnings of $0.85 per share from the same period last year. The company reported $210.77 million in sales this quarter. This is a 17.32 percent increase over sales of $179.66 million the same period last year.

Yiren Digital Q3 2024 EPS $0.57 Down From $0.85 YoY, Sales $210.77M Up From $179.66M YoY

The solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM Platform with high accuracy and efficiency.

Health Care

SOPH

SOPHiA GENETICS Announced The Global Launch Of MSK-impact Powered With Sophia DDM From The Association For Molecular Pathology Annual Meeting

Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) reported quarterly losses of $(1.12) per share. This is a 12.5 percent increase over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $2.06 billion which beat the analyst consensus estimate of $1.91 billion by 7.98 percent. This is a 12.80 percent increase over sales of $1.82 billion the same period last year.

BZUN

Baozun Q3 2024 GAAP EPS RMB(1.12) Up From RMB(1.28) YoY, Sales RMB2.06B Beat RMB1.91B Estimate

Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) reported quarterly losses of $(0.86) per share. This is a 10650 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $12.35 million in sales this quarter. This is a 37.92 percent decrease over sales of $19.90 million the same period last year.

Yunji Q3 EPS $(0.86) Down From $(0.01) YoY, Sales $12.35M Down From $19.90M YoY

Subsea 7 (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SUBCY#OTC">SUBCY</a>) reported quarterly earnings of $0.31 per share. This is a 181.82 percent increase over earnings of $0.11 per share from the same period last year. The company reported $1.83 billion in sales this quarter. This is a 16.22 percent increase over sales of $1.58 billion the same period last year.

SUBCY

Subsea 7 Q3 EPS $0.31 Up From $0.11 YoY, Sales $1.83B Up From $1.58B YoY

<ul>
<li>In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all patients were either undetectable or minimal, highlighting LP-310's potential to deliver localized therapeutic effects while minimizing systemic exposure. Additionally, all patients tolerated LP-310 without significant adverse reactions.</li>
<li>Following a successful internal safety evaluation of the first dose cohort, the trial has received approval to advance to the next stage of the trial, which will evaluate a higher dose of 0.5 mg of LP-310.</li>
</ul>

Biotech

LIPO

Lipella Pharmaceuticals Has Completed Dosing For The First Cohort In Its Phase 2A Trial Of LP-310, A Liposomal-tacrolimus Oral Rinse Being Developed For Oral Lichen Planus, Topline Data Is Expected By Year-end And Complete The Trial By Mid-2025

KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) reported quarterly earnings of $1.53 per share which missed the analyst consensus estimate of $1.57 by 2.55 percent. The company reported quarterly sales of $22.58 billion which missed the analyst consensus estimate of $23.46 billion by 3.74 percent. This is a 825.16 percent increase over sales of $2.44 billion the same period last year.

BEKE

KE Holdings Q3 2024 Adj EPADS RMB1.53 Misses RMB1.57 Estimate, Sales RMB22.58B Miss RMB23.46B Estimate

TD Cowen analyst Andrew Charles reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and maintains $50 price target.

Price Target

Reiteration

Analyst Ratings

JACK

TD Cowen Reiterates Hold on Jack In The Box, Maintains $50 Price Target

Needham analyst Bernie McTernan maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $200 to $235.

Needham Maintains Buy on Wix.com, Raises Price Target to $235

Delta Air Lines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NASDAQ">DAL</a>) CEO Ed Bastian has suggested that President-elect Donald Trump&#8216;s administration could provide a &#8220;breath of fresh air&#8221; for the airline industry, criticizing what he perceives as government &#8220;overreach&#8221; during President Joe Biden&#8216;s era.
What Happened: Speaking ahead of the company&#8217;s investor day, Bastian signaled potential regulatory changes that could significantly impact the aviation sector, <a href="https://apnews.com/article/delta-airlines-trump-biden-regulation-c4393d5f763d95c8286d4069563032dc#">reported</a> the Associated Press on Thursday.
The airline executive&#8217;s comments reflect a broader sentiment among industry leaders who anticipate a more business-friendly regulatory environment. 
Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) CEO Robert Jordan similarly expressed hope for a Department of Transportation that might be &#8220;less aggressive&#8221; in rule-making, highlighting growing frustration with current consumer protection regulations.
See Also: <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">Bitcoin Hits $95K For The First Time Ever, Ethereum, Dogecoin Flat As Trump&#8217;s Crypto Policy Takes Shape</a>
Delta&#8217;s financial performance provides context for these expectations. The airline reported a robust $2.6 billion profit in the first nine months of 2024, with projected fourth-quarter adjusted profit between $1.60 and $1.85 per share. The company expects 2025 revenue growth in mid-single digits, positioning itself strongly amid potential regulatory shifts.
Why It Matters: Wall Street appears cautiously optimistic about <a href="https://www.benzinga.com/general/travel/24/11/42014787/delta-united-alaska-air-are-top-analyst-picks-in-airline-sector">the airline sector&#8217;s future</a>. Goldman Sachs has resumed coverage of major airlines, providing Delta with a &#8220;Buy&#8221; rating and an $83 price target. Analysts expect continued supply constraints through 2025, with a focus on airlines&#8217; ability to adapt to changing market conditions.
The potential appointment of Sean Duffy as Transportation Secretary could herald broader changes across the transportation sector. Industry <a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads">observers speculate about the potential streamlining of regulations</a>, enhanced infrastructure focus, and possible modifications to electric vehicle and autonomous driving policies.
Price Action: Delta Air Lines closed at $63.64 on Wednesday, down 1.71% for the day. In pre-market trading, the stock was down 0.5% at the time of writing. Year to date, the stock has surged by 57.33%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/11/42044634/653125">Dave Ramsey Recalls The Day American Express Called His Wife, Asking Why Stay &#8216;With A Man That Won&#8217;t Pay His Bills.&#8217; Here&#8217;s What He Did Next</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Delta Chief Says Trump Could Be A 'Breath Of Fresh Air' For Aviation Industry

William Blair analyst Dylan Carden downgrades Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Outperform to Market Perform.

Downgrades

ULTA

William Blair Downgrades Ulta Beauty to Market Perform

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) released their September quarter results just a day apart. Target&#8217;s management highlighted that its customers were most active during sales and promotional events, while Walmart&#8217;s leadership attributed 75% of its market share growth to households earning six-figure incomes.
Target&#8217;s executive vice president and chief commercial officer company Rick Gomez said that their consumers &#8220;know there are deals to be found, they&#8217;re willing to wait for sales and willing to search across multiple retailers.&#8221; While the latter&#8217;s chief executive officer, Doug McMillon attributed <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">75% of their market share gains</a> to "households earning more than $100,000."
Also read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">Walmart Market Share Surges As Six-Figure Income Households Drive 75% Of Growth In Q3: &#8216;People Come To Us To Shop As A Primary Destination&#8217;</a>
What Happened: Gomez highlighted that Target&#8217;s consumers were looking for promotions with an example. &#8220;Our Target Circle week this quarter was one of our biggest yet. However, we saw a more pronounced sales dip both the week before and the week after the event, showing just how planful consumers are in seeking out promotions when they shop.&#8221;
&#8220;Similarly, we saw consumers lean into everyday essential stock-up promotions throughout the quarter to further stretch their monthly budgets. We saw a strong reaction to promotions throughout the quarter,&#8221; he added.
On the flip side, John David Rainey the chief financial officer of Walmart re-affirmed his CEO&#8217;s view and said, &#8220;we're seeing higher engagement across income cohorts with upper-income households continuing to account for the majority of our share gains.&#8221;
Why It Matters: Shares of Target Corporation plunged by 21.41% to close at $121.72 apiece, on Wednesday, as compared to a 0.16% advance in the NYSE Composite Index. <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target&#8217;s third-quarter</a> adjusted earnings per share of $1.85, missed the street view of $2.30. Quarterly total revenue of $25.67 billion (+1.1% year over year) missed the analyst consensus estimate of $25.90 billion.
Brian Cornell, chair and chief executive officer of Target said, "We encountered some unique challenges and cost pressures that impacted our bottom-line performance.&#8221; The third-quarter gross margin rate decreased by 0.2 percentage points to 27.2%.
Also read: <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks</a>
On Tuesday, <a href="https://www.benzinga.com/pressreleases/24/11/b42058916/walmart-reports-strong-revenue-growth-of-5-5-with-operating-income-growing-faster-at-8-2">Walmart&#8217;s third-quarter results</a> beat estimates and the fiscal 2025 guidance was raised. Its shares rose 3% on Tuesday, while it was further up by 0.67% to $87.18 apiece as per Wednesday&#8217;s close.
Walmart&#8217;s ales were at $169.59 billion, up 5.5% year over year or 6.2% (at constant currency), beating the consensus of $167.72 billion. The gross margin rate was up 21 bps to 24.2% aided by improvement in the Walmart U.S. Operating income was up by $0.5 billion or 8.2% year over year at $6.7 billion.
Price Action: On a year-to-date basis, Walmart has surged by 64.19%, while Target is down by 14.94%, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data. The NYSE Composite Index was up 17.26% in the same period. In Thursday&#8217;s premarket, TGT shares were up 0.5%. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="272" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png" alt="" class="wp-image-658433" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-300x80.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-768x204.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1536x408.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT.png 1741w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read next: <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a>
Image via Flickr/ Mike Mozart

Earnings Beats

Earnings Misses

Target Says Shoppers Wait For 'Deals' A Day After Rival Walmart Credits Market Gains To Wealthy Households: TGT Edges Up Marginally In Thursday Premarket

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Underperform to Sector Perform and maintains the price target from $4 to $4.

Upgrades

SAGE

RBC Capital Upgrades Sage Therapeutics to Sector Perform, Maintains Price Target to $4

Piper Sandler analyst Brent Bracelin reiterates Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Overweight and raises the price target from $165 to $185.

SNOW

Piper Sandler Reiterates Overweight on Snowflake, Raises Price Target to $185

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) new vehicle registrations in the EU are continuing to drop, <a href="https://www.benzinga.com/tech/24/11/41892379/tesla-offers-a-year-of-supercharging-for-free-in-europe-as-it-chases-record-q4-deliveries-to-outpace-a-slowdown">threatening the company&#8217;s global EV delivery target</a> for the year.
What Happened: Tesla had 11,088 vehicle registrations in the European Union in October, marking a drop of 21% from the corresponding period last year, according to data from the European Automobile Manufacturers' Association (ACEA). 
This is despite battery electric vehicle registrations rising 2.4% in the EU last month to 124,907 units on the back of growing popularity in Denmark and the Netherlands. 
Tesla had 192,661 new vehicle registrations in the EU from January through the end of October, marking a drop of over 11% year-on-year. 
For the full year 2023, Tesla delivered 1,808,581 vehicles around the globe. To mark a growth over last year, the company has to deliver at least 514,926 vehicles in the three months through the end of December. Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an ambitious target.
Why It Matters: In the third quarter, Tesla reported deliveries of 462,890 vehicles, up 6.4% year-over-year and up 4.3% quarter-over-quarter.
Deliveries fell 8.5% year-on-year in the first quarter and by 4.8% in the second quarter.
According to Tesla researcher Troy Teslike, the low sales in Europe are likely to impact Tesla&#8217;s aim to prevent a drop in yearly deliveries. 
&#8220;Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are down too,&#8221; <a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher">Teslike said</a> in a post on X earlier this week.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are… <a href="https://t.co/fflyf175xp">https://t.co/fflyf175xp</a>
&mdash; Troy Teslike (@TroyTeslike) <a href="https://twitter.com/TroyTeslike/status/1858430634315943990?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Tesla stock fell 1.2% on Wednesday to close at $342.03, and declined over 1% in premarket trading on Thursday. Year-to-date, the stock is up 37.7%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways" target="_blank" rel="noreferrer noopener">Jim Cramer Thinks Trump's Plans For Robotaxis Are ‘Fanciful,' But He Is Still Bullish On Tesla Stock: ‘The Musk Premium Will Work Its Magic In Other Ways'</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Registrations Drop By Over 20% In October In EU, Possibly Hindering Its 2024 Global EV Delivery Target

Macquarie analyst Austin Yun upgrades Piedmont Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) from Underperform to Neutral and announces $13.5 price target.

Macquarie Upgrades Piedmont Lithium to Neutral, Announces $13.5 Price Target

<ul>
<li>Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029.&nbsp;</li>
<li>The company remains on track to deliver core operating income margin1 of 40%+ by 2027, benefiting from continued strong sales growth and productivity improvements.</li>
<li>"Novartis has completed its transformation into a pure-play innovative medicines company, with deep expertise and capabilities across our core therapeutic areas and technology platforms. Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more than 15 submission-enabling readouts in the coming years to further bolster our growth profile," said Vas Narasimhan, CEO of Novartis. "Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029. Taken together, we remain confident in our focused strategy and ability to deliver sustainable value creation for shareholders."</li>
</ul>

Large Cap

Guidance

Novartis Upgrades Its Mid-term Guidance. Previous Guidance For +5% Sales CAGR 2023-2028 Was Upgraded To +6%, Driven By Strong Momentum Of In-market Growth Drivers And Upcoming Launches, Most Of Which Have Expected US Exclusivity In 2030's Or Beyond

HSBC analyst Carlos Gomez-Lopez initiates coverage on Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Buy rating and announces Price Target of $33.

Initiation

HSBC Initiates Coverage On Marex Group with Buy Rating, Announces Price Target of $33

The Offering is expected to close on or about November 25, 2024, subject to customary closing conditions.
The Company estimates that the net proceeds from the sale of the Notes, after deducting initial purchaser discounts but before deducting the other estimated expenses of the offering, will be approximately US$124.2 million (or approximately US$143.5 million if the initial purchasers exercise their option to purchase additional Notes in full). The Company intends to use the net proceeds from the Offering (including any net proceeds from the sale of any additional Notes that may be sold should the initial purchasers exercise their option to purchase additional Notes) for the construction of copper-gold mining projects outside of China, for the exploration and development of other projects and for working capital.

Silvercorp Metals Prices $130M 4.75% Convertible Senior Notes Due 2029

Ayr Wellness misses top-line and bottom-line estimates; initiates Q424 outlook

Reports Q3 revenue $114.3M vs. $114.4M last year. Steve Cohen, Interim CEO of AYR, said, "Our third quarter performance reflected ongoing macroecon...

Ayr Wellness reports Q3 EPS (44c) vs. (25c) last year

Ayr Wellness (TSE:AYR.A) has released an update. AYR Wellness reported a challenging third quarter, affected by economic pressures and increased co...

AYR Wellness Faces Challenges Amid Expansion Plans

Ayr Wellness Inc. (AYRWF) Q3 2024 Earnings Call Transcript

Ayr Wellness continues to maintain a strong share in Florida's medical market and sees potential for revenue growth as its new indoor cultivation facility comes online next year.

Ayr Wellness Q3 Financials: Net Loss Was Down; Adj. EBITDA Was Up

Ayr Wellness Inc. ( ($AYRWF) ) has released its Q3 earnings. Here is a breakdown of the information Ayr Wellness Inc. presented to its investors. A...

Ayr Wellness Inc. Reports Q3 2024 Results Amid Market Challenges

Cannabis stocks gain as Trump picks pro-marijuana Congressman Gaetz for AG post

Canaccord analyst Matt Bottomley lowered the firm's price target on Ayr Wellness (AYRWF) to C$4.75 from C$6 and keeps a Speculative Buy rating on t...

Ayr Wellness price target lowered to C$4.75 from C$6 at Canaccord

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

AYR Wellness (AYRWF) announced an expansion of its Later Days brand to now include a line of pocket-friendly vapes packed with smooth, refreshing f...

Ayr Wellness launches Later Days fruit-flavored vape collection

ATAI

AYWWF

CANN

CMPS

CRON

CVSI

CYBN

ENVB

GRWG

IMCC

MEDIF

MSOS

NLCP

RLMD

SHFS

TLRY

TSNDF

VREOF

YOLO

Press Releases

AYR Wellness Launches Adult-Use Sales in Ohio

AYR Wellness Reports Second Quarter 2024 Results

AYR Cannabis Dispensary Celebrates Opening of Manchester, Connecticut Retail Location

AYR Cannabis Dispensary Expands Retail Footprint in Florida with Two New Dispensaries

AYR Wellness Secures Conditional Approval to Establish Vertical Medical Cannabis Operations in Virginia

Management

AYR Wellness Announces Changes to Management

AYR Wellness to Hold Third Quarter 2024 Conference Call on November 13th at 8:30 a.m. ET

Amethyst Health, a Partnership Between Black Star Wellness and AYR Wellness, Conditionally Awarded Vertically Integrated Medical License in New York

AYR Wellness Reports Third Quarter 2024 Results

AYR Launches Later Days Fruit-Flavored Vape Collection

CSE:AYR

CSE:AYR-A

CSE:AYR.A

Ayr Wellness

Roth MKM

Cantor Fitzgerald

Needham

Seaport Global

2024年第2四半期の大部分の大麻企業の財務業績が出揃い、その結果から興味深いトレンドが浮かび上がってきた。その1つが、米国のマルチステート・オペレーター（MSO）が供給チェーンにおけるコストと効率を改善しているという点だ。
MSOが風雲急を告げてきたことは驚くべきことではなく、かつその回復力が示されてきたのも理解できる。これまで低い卸売価格という圧力に直面し、小売業界での競争の激化と追加の課税に面してきたが、これらの大半の企業は、そのコスト業績を維持し、あるいはいくつかのケースでは改善することに成功してきたのだから。
<h3 class="wp-block-heading">財務詳細</h3>
バリディアン（Viridian）の<a href="https://dealtracker.viridianca.com/chart-of-the-week/">データ分析</a>によると、トップ8のMSOのうち6社の売上高に対する売上原価（COGS）の割合が昨年と比較して減少した。この削減は、これらの企業が課題に直面しながらも生産コストをより効率的に管理していることを示している。比較の対象には、Green Thumb Industries（OTC：<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>）、Curaleaf（OTC：<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>）、Trulieve（CSE：<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>）（OTCQX：<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>）、Verano（OTC：<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>）、Cresco Labs（OTC：<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>）、Terrascend（OTC：<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>）、AYR（OTC：<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>）およびAscend Wellness（OTC：<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>） が含まれる。ただし、AYRとTerrAscendはCOGSが増加した。これは、彼らが他の企業よりもより大きな運用上の課題に直面していることを示している。
さらに、このうちの6社は、2024年第2四半期における2023年第2四半期との比較で、売上高に対する売上、一般および管理（SG&amp;A）費用が低下した。この傾向は、これらの企業が自分たちのベルトを締め直し、支出についてより規律あるものになり、供給チェーンにおいて効率的に動くことを反映している。売上費用の削減は市場状況を反映したものとみられる。オハイオ州とニューヨーク州に新しいマーケットが拡大するにつれて、これらの企業は売上の増加を期待しており、それによって年の後半にはさらに財務業績が向上するはずだ。
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-490763" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/12160625/unnamed-2.png" sizes="(max-width: 630px) 100vw, 630px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/12160625/unnamed-2.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/12160625/unnamed-2-300x194.png 300w" alt="" width="630" height="407" /></figure>
関連記事: <a href="https://www.benzinga.com/markets/cannabis/24/07/39806043/cannabis-stocks-canadian-companies-outperformed-american-counterparts-last-week">大麻株：先週、カナダ企業の方が米国企業をアウトパフォーム</a>
<h3 class="wp-block-heading">MSOと大麻業界における役割の理解</h3>
MSOは複数の州にわたる栽培、加工、小売施設を管理する会社であり、米国の独自の法的枠組みのために同国の大麻市場においてさらに重要なプレーヤーになっている。
大麻が連邦レベルで未だに違法とされているため、ビジネスは州ごとの規制、法則および<a href="https://www.benzinga.com/markets/cannabis/24/08/40176980/state-by-state-price-of-weed-across-the-u-s-in-august-2024">価格</a>といった複雑な規制網を航行せねばならない。MSOはこのような課題を処理するために設計されており、それによって彼らは異なる法律を守りながら、州をまたいでの業務展開を可能にしているのだ。この戦略により、MSOは市場拡大に伴う経済規模の利点を活かし、コストを引き下げ、効率を向上させることができる。ただし、州ごとの規制を遵守することが重要であるため、それによって大きなコストが生じてしまう。
最新のQ2の報告書は、大半のMSOがコスト削減に焦点を当てていることを示唆している。大麻の<a href="https://www.benzinga.com/markets/cannabis/24/07/39892433/dea-rescheduling-of-cannabis-could-create-over-50-000-jobs-industry-group-notes-in-public-commen">スケジューリングの可能性</a>があれば、これは全体の<a href="https://www.benzinga.com/markets/cannabis/24/05/38885460/finally-tax-refunds-these-cannabis-companies-will-get-the-most-money-back-if-rescheduling-happen">税制負担を削減する</a>ことによって、それによってそれらの財務業績を大幅に向上させる可能性がある。
<ul>
<li>次を読む: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39514459/u-s-dollar-soars-how-does-this-threaten-your-cannabis-investments-confidential-insi">米ドルが急騰：これがあなたの大麻投資に脅威を与える理由、機密情報の洞察</a></li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" class="wp-image-490829" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/12164248/CCC-Oct-24-Banner-1-37.gif" alt="" width="970" height="250" /></a></figure>

ペンシルベニア州が最近承認した予算には、大麻企業であるJushi Holdings（OTC：<a class="ticker" href="https://www.benzinga.com/stock/JUSHF#OTC">JUSHF</a>）およびTILT Holdings（OTC：<a class="ticker" href="https://www.benzinga.com/stock/TILT#OTC">TILT</a>）のような企業にとって大きな打撃を与える、大麻の娯楽利用の合法化が除外されています。
ジョシュ・シャピロ知事が支援したこの動きに対し、民主党と共和党に分かれた州議会からは<a href="https://www.spotlightpa.org/news/2024/06/pennsylvania-marijuana-recreational-legislature-passage-budget-josh-shapiro/">反対</a>が出てしまいました。規制に関する合意については、民主党が支配する州下院で合意に達しようとする一方で、大麻の娯楽利用の合法化に反対する共和党が支配する州上院は合意に達しませんでした。
新しい<a href="https://www.pa.gov/en/governor/newsroom/2024-press-releases/governor-shapiro-signs-bipartisan-2024-25-budget--investing-in-e.html">予算</a>は幅広い経済的および社会的投資に焦点を当てていますが、娯楽利用の大麻についての規定は除外しています。主な投資先は、K-12公共教育のための11.1億ドル、企業の誘致のためのサイト開発のための5億ドル、および家庭およびコミュニティを対象としたサービスのための3億5480万ドルが含まれています。
<h3>遅れの中でのJushiとTILTの戦略的動向</h3>
Jushi Holdings（OTCQB）とTILT Holdings（OTCQB）は、ペンシルベニア州での医療大麻の販売から娯楽大麻の販売への移行によって成長が促進されると予測し、大規模な投資を行っています。
Jushiの現在の企業価値は過小評価されていると見なされ、規制の透明性が与えられれば大きな上昇余力があるということを示唆しています。 Zuanic＆AssociatesのシニアアナリストPablo Zuanic氏は、「ペンシルベニア州が娯楽大麻の販売を開始すれば、Jushiの時価総額は250％以上急増する可能性がある」と述べています。
一方、TILT HoldingsはStandard Farmsを運営しており、ペンシルベニア州での事業拡大のために1050万ドルの資金調達契約を締結しました。 これらの資金は、保健省（Department of Health）の許可を受けたディスペンサリーの構築に充てられます。
「ペンシルベニア州が、TILTのStandard Farmsのような小規模な独立系栽培業者がこの新興の市場で競争できるように、我々は賞賛します」と、TILTのCEOであるTim Conder氏は<a href="https://www.benzinga.com/markets/cannabis/24/05/38741310/tilt-holdings-bold-financing-move-how-this-cannabis-companys-escalating-interest-rates-impact-it">述べています</a>。
しかし予想される娯楽市場がないとすると、6か月後にかなり高騰する拡大ローンの金利がTILTの財務モデルに圧迫を与える可能性があります。
<h3>ティム・シーモア氏は州による大麻の合法化をどう見るか</h3>
CNBS Amplify Seymour Cannabis ETF（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/CNBS#NYSE">CNBS</a>）のポートフォリオマネージャーであるTim Seymour氏は、連邦政府の変化よりも州レベルでの大麻の合法化の重要性を強調しました。 「大麻セクターにおける実際の経済は、成長している消費者基盤向けに積極的に製品を販売している企業によって推進されています」と、Seymour氏は<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39344068/not-dc-but-the-states-tim-seymour-discusses-how-red-states-could-catalyze-cannabis-">語りました</a>。
彼は、ペンシルベニア州のような市場が、大麻業界の成長を促進していると指摘し、州レベルの決定が大麻産業の未来にとって重要であることを示唆しています。
関連記事：
<h3>ペンシルベニア州における大麻企業</h3>
JushiとTILTの両社は、ペンシルベニア州の予算における娯楽利用の大麻の除外がもたらす不確実な規制環境に適応しなければなりません。
予算から娯楽利用の大麻が除外されたことは、分かれた州議会での合意形成の複雑さを象徴しています。Seymour氏が指摘したように、「州レベルの法制化は、実際の産業の成長につながる製品を消費者の手に届けるものです」。
Zuanic氏は、「<a href="https://www.benzinga.com/markets/cannabis/24/02/37242307/jushi-holdings-revs-up-unleashing-torque-in-pennsylvania-and-virginias-cannabis-expansion">娯楽利用の大麻が合法化されない</a>場合、Jushi Holdingsは医療大麻市場に制限されることで成長が制約されるだろう」と述べたように、Jushiもまた州の不確実な規制環境に適応しなければなりません。
販売の勢いと利益率の面で競合他社に遅れをとっているにも関わらず、Jushiは業務を合理化し、EBITDAマージンを大幅に改善しています。 Zuanic氏は、12月2024年に支払期日を迎える約6,500万ドルの借金の<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39470114/debt-deadline-looms-how-cannabis-companies-financial-health-could-impact-your-portf">返済の取り組み</a>に加え、Jushiの財務状況は管理可能であると考えています。
<h3>予算承認後の市場動向</h3>
2024年7月15日（月）、午後12時過ぎ、Jushi Holdings（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/JUSHF#NYSE">JUSHF</a>）の株価は0.592ドルで、2.8449％下落し、投資家の信頼が低下していることを示しています。取引高は8339株で、市場活動は抑制的であることを示しています。時価総額は約1億1600万ドルであり、大麻セクターの中では比較的小さな企業です。
TILT Holdingsの株価は0.02211ドルで、10.55％上昇し、これは投資家からのポジティブな評価か、または最近のニュースへの反応であると考えられます。株価は6,150で、これは中規模の取引高で、時価総額は約850万ドルであり、大麻セクターの中でマイクロキャップ株式として位置づけられています。
これらは、ペンシルベニア州で<a href="https://www.benzinga.com/topic/pennsylvania-cannabis">運営している最も重要なMSO</a>の一部です。
<ul>
<li>Curaleaf Holdings（OTC：<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>）</li>
<li>Trulieve Cannabis（OTC：<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>）</li>
<li>Cresco Labs（OTC：<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>）</li>
<li>Green Thumb Industries（OTC：<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>）</li>
<li>Ayr Wellness（OTC：<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>）</li>
<li>Verano Holdings（OTC：<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>）</li>
<li>TerrAscend（OTC：<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>）</li>
<li>The Cannabist Co.（OTC：<a class="ticker" href="https://www.benzinga.com/stock/CCHWF#OTC">CCHWF</a>）</li>
</ul>
次の一手：　
これらの問題については、10月8日から9日まで開催されるベンジンガ・カンナビス・キャピタル・カンファレンス（Benzinga Cannabis Capital Conference）で大いに議論されることでしょう。大麻業界の将来における投資の意味について更に多くの見識を得るために、ぜひ私たちにご参加ください。このカンファレンスで、大手企業のトップエグゼクティブ、投資家、提唱者、立法者の皆様の素晴らしいご意見をお聞きになりませんか。　<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">チケットをお求めください</a>。
写真：AIによる生成画像。

フロリダ州の知事であるロン・デサンティス（共和党）は、2024年11月の選挙でフロリダ州民が投票する大麻合法化修正案について、別の非難を浴びせた。今回は、同氏がK-12スクールの近くで大麻を吸うと考えられる人々を非難している。
「小学校のような教育機関の近くで大麻を吸う人が横切ることを認可してもいいのか？」とデサンティス氏は水曜日、マイアミで行われたイベントで記者団に語った。「フロリダ州にとってそれがいい結果を生むと思わない」と非難した。
この提案は、Amendment 3として知られており、フロリダ最高裁判所によって最近<a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d">11月の投票用紙に進むことが承認された</a>。この修正案は、Smart and Safe Floridaによって組織され、その実、州がタバコの公共での消費を規制しているように、立法府に対して「屋外での大麻使用と公共での大麻使用を制限するための権限」を与えるものだ。
<h1 class="wp-block-heading">それでもデサンティス知事は批判を続ける</h1>
「この修正法はこれまでで最も幅広いものであり、フロリダ州の全地域で公然での大麻使用を許可することと同意義と捉えている」とデサンティス氏は述べた（<a href="https://floridapolitics.com/archives/670027-gov-desantis-slams-marijuana-amendment-again-warns-of-toking-up-near-schools/">Florida Politicsの報告</a>）。「これは家族にとって良いことではないし、老人にとっても良いことではない。」
そして、デサンティス知事は、自身が語っている間に数マイル先のハリウッド、フロリダの<a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> で開催されたイベントで、フロリダ州の修正案を支持する大麻企業を激怒させた。
「この法案のために数千万ドルを使用する意義を理解できない。大麻企業はこの修正案によって莫大な利益を上げることができる。」と非難的な言葉を口にした。
Trulieve Cannabis Corp（OTCQX：<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>）をはじめとする大麻会社は名前は出ていないが、これまでに少なくとも1,500万ドル以上の資金を提供して修正案を支持している。この提案に資金を提供している会社は、Verano Holdings Corp（OTCQX：<a href="https://www.benzinga.com/stock/vrnof#OTCQX">VRNOF</a>）、Curaleaf Holdings Inc（OTCQX：<a href="https://www.benzinga.com/stock/curlf#OTCQX">CURLF</a>）、AYR Wellness Inc（OTCQX：<a href="https://www.benzinga.com/stock/ayrwf#OTCQX">AYRWF</a>）、Cresco Labs Inc。（OTCQX：<a href="https://www.benzinga.com/stock/crlbf#OTCQX">CRLBF</a>）、Green Thumb Industries Inc（OTCQX：<a href="https://www.benzinga.com/stock/gtbif#OTCQX">GTBIF</a>） 、INSA, Inc。含まれている。
写真：ウィキメディア・コモンズ<a href="https://www.pexels.com/photo/close-up-photo-of-cannabis-plant-7667883/" target="_blank" rel="noreferrer noopener">Kindel Media</a>による写真

Comments

Ayr Wellness

ニュース

最新ニュース Ayr Wellness (OTC:AYRWF) 株価情報

月曜日, 8 12, 2024

火曜日, 7 16, 2024

木曜日, 4 18, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル